Literature DB >> 2060723

Oxygen free radical effects in sciatic nerve in experimental diabetes.

P A Low1, K K Nickander.   

Abstract

We previously reported the presence of endoneurial hypoxia, ischemia, impairment of the blood-nerve barrier, and reduction of norepinephrine and 6-ketoprostaglandin F1 alpha in chronic streptozocin-induced diabetic neuropathy (SDN) and interpreted these findings as suggesting the involvement of oxygen free radicals (OFRs) but did not directly measure indices of OFR activity. In this study, we report on sciatic nerve conjugated dienes, hydroperoxides, norepinephrine, and malondialdehyde in SDN at 1, 4, and 12 mo in male Sprague-Dawley rats. Severe hyperglycemia was present throughout in diabetic rats. Conjugated dienes were consistently increased at all time points, hydroperoxides were consistently reduced, and malondialdehyde was not significantly different in diabetes compared with controls. These findings are consistent with increased OFR activity in experimental diabetes. It is necessary to monitor several indices of OFR activity in a metabolically active tissue such as the peripheral nerve.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060723     DOI: 10.2337/diab.40.7.873

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  25 in total

1.  Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy.

Authors:  Roman Stavniichuk; Hanna Shevalye; Sergey Lupachyk; Alexander Obrosov; John T Groves; Irina G Obrosova; Mark A Yorek
Journal:  Diabetes Metab Res Rev       Date:  2014-11       Impact factor: 4.876

2.  Comparison of the effects of aminoguanidine and L-carnitine treatments on somatosensorial evoked potentials in alloxan-diabetic rats.

Authors:  O Yildiz; M Ozata; A Ozkardeş; G Deniz; M Yildirimkaya; A Corakçi; M Yardim; M A Gündoğan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

3.  Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost.

Authors:  M A Cotter; K C Dines; N E Cameron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

Review 4.  Vascular factors in diabetic neuropathy.

Authors:  S Tesfaye; R Malik; J D Ward
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

5.  ACTH4-9 analogue ORG 2766 can improve existing neuropathy in streptozocin-induced diabetic rats.

Authors:  B Bravenboer; A C Kappelle; T van Buren; D W Erkelens; W H Gispen
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

6.  Decreased glutathione peroxidase activity in sciatic nerve of alloxan-induced diabetic mice and its correlation with blood glucose levels.

Authors:  C Hermenegildo; A Raya; J Romá; F J Romero
Journal:  Neurochem Res       Date:  1993-08       Impact factor: 3.996

7.  Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids.

Authors:  C Karasu; M Dewhurst; E J Stevens; D R Tomlinson
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

8.  The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats.

Authors:  N E Cameron; K C Dines; M A Cotter
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

9.  Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.

Authors:  M J Stevens; S A Lattimer; M Kamijo; C Van Huysen; A A Sima; D A Greene
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

10.  Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats.

Authors:  N E Cameron; M A Cotter; V Archibald; K C Dines; E K Maxfield
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.